Interaction of cocaine-, benztropine-, and GBR12909-like compounds with wild-type and mutant human dopamine transporters: molecular features that differentially determine antagonist-binding properties.
about
Nonclassical pharmacology of the dopamine transporter: atypical inhibitors, allosteric modulators, and partial substratesRole of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuseThe atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitorsIn vitro binding assays using (3)H nisoxetine and (3)H WIN 35,428 reveal selective effects of gonadectomy and hormone replacement in adult male rats on norepinephrine but not dopamine transporter sites in the cerebral cortex.Hyperdopaminergic tone in HIV-1 protein treated rats and cocaine sensitization.Studies of the biogenic amine transporters. 14. Identification of low-efficacy "partial" substrates for the biogenic amine transportersEvolution of a Compact Photoprobe for the Dopamine Transporter Based on (±)-threo-Methylphenidate.Site-directed mutations near transmembrane domain 1 alter conformation and function of norepinephrine and dopamine transportersInteraction of tyrosine 151 in norepinephrine transporter with the 2β group of cocaine analog RTI-113.Dopamine transporter oligomerization: impact of combining protomers with differential cocaine analog binding affinitiesDopamine transporter-dependent and -independent striatal binding of the benztropine analog JHW 007, a cocaine antagonist with low abuse liability.Novel multifunctional pharmacology of lobinaline, the major alkaloid from Lobelia cardinalis.Novel C-1 substituted cocaine analogs unlike cocaine or benztropine.Importance of cholesterol in dopamine transporter function.Relations between stimulation of mesolimbic dopamine and place conditioning in rats produced by cocaine or drugs that are tolerant to dopamine transporter conformational change.Intermittent cocaine self-administration produces sensitization of stimulant effects at the dopamine transporter.A catecholamine transporter from the human parasite Schistosoma mansoni with low affinity for psychostimulants.Characterization of [³H]CFT binding to the norepinephrine transporter suggests that binding of CFT and nisoxetine is not mutually exclusive.Bivalent phenethylamines as novel dopamine transporter inhibitors: evidence for multiple substrate-binding sites in a single transporter.A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone.Mechanism for cocaine blocking the transport of dopamine: insights from molecular modeling and dynamics simulations(±)-2-(N-tert-Butylamino)-3'-[(125)I]-iodo-4'-azidopropiophenone: a dopamine transporter and nicotinic acetylcholine receptor photoaffinity ligand based on bupropion (Wellbutrin, Zyban).Binding site residues control inhibitor selectivity in the human norepinephrine transporter but not in the human dopamine transporterConformational state interactions provide clues to the pharmacochaperone potential of serotonin transporter partial substrates.Synthesis and Cytotoxicity Evaluation of Tropinone Derivatives.Targeting the FKBP51/GR/Hsp90 Complex to Identify Functionally Relevant Treatments for Depression and PTSD
P2860
Q26853319-A168DB78-DCCF-4BC3-A2F6-6A1C1CA5507FQ28306056-04E1E80F-FE1C-43C2-94EE-E915EAEF7063Q28477546-240A9ACC-5A88-4B7B-AA6B-375BBF1A54B0Q30482834-6E5C48C0-8924-4012-9AED-217400CA27F4Q33701016-A0FB3DB7-723F-4DF1-8DDD-9B63857085DFQ34249270-446C8A15-74C3-4E9D-A70A-EFB0A44725D9Q34306186-4A5DD663-123A-42D2-BF48-68E4EA79F828Q34701009-5583C1DF-70B8-4125-BAA2-1BB302D083C1Q35017258-DD5039BB-4ECC-4F15-AC9C-97D13E6ED0B6Q35371135-7F9C9CD7-497A-4479-A8F6-F955E0226A1CQ35454366-B53F954F-EDAE-4E30-8AFC-20DD66D878F0Q35997207-6A325346-EBF0-4244-853A-85890AD09D77Q36335545-CCE45C85-CE05-4E6A-92B2-C35D8081AE5BQ36453517-B68011C4-3F6B-47AF-BFC8-B886164E1A73Q37135116-E55909A0-6CD8-451F-AACA-121B50BB3CD8Q37707736-52063FE2-C8C4-4270-A5B4-201554F4250EQ39161231-757F155F-5287-4070-B794-52A61223B5BFQ39293366-13473865-11DA-4401-9F3A-DE655916391CQ39753107-6D85CE9A-2965-4249-BAAF-FE0376018A70Q39851539-78120106-755D-4760-AB8B-1C8CFFAFED81Q39938422-D0EACDC2-0708-4908-8D28-18AF84F7F4BEQ40079534-3FC8C33B-05B3-43F6-B7EC-76B83526392FQ40390385-9E82B502-59D1-40D8-B940-F6DF1C3EABCDQ41861390-6812BB08-50F2-474E-BE53-E7499D6583CFQ42058614-6E1987D9-110D-4B8D-B5DE-20ACBEAF2904Q58433147-84B2634A-75E0-4363-95C5-73FE83467505
P2860
Interaction of cocaine-, benztropine-, and GBR12909-like compounds with wild-type and mutant human dopamine transporters: molecular features that differentially determine antagonist-binding properties.
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Interaction of cocaine-, benzt ...... antagonist-binding properties.
@ast
Interaction of cocaine-, benzt ...... antagonist-binding properties.
@en
Interaction of cocaine-, benzt ...... antagonist-binding properties.
@nl
type
label
Interaction of cocaine-, benzt ...... antagonist-binding properties.
@ast
Interaction of cocaine-, benzt ...... antagonist-binding properties.
@en
Interaction of cocaine-, benzt ...... antagonist-binding properties.
@nl
prefLabel
Interaction of cocaine-, benzt ...... antagonist-binding properties.
@ast
Interaction of cocaine-, benzt ...... antagonist-binding properties.
@en
Interaction of cocaine-, benzt ...... antagonist-binding properties.
@nl
P2093
P2860
P50
P1476
Interaction of cocaine-, benzt ...... antagonist-binding properties
@en
P2093
Maarten E A Reith
Manoj Mishra
Nianhang Chen
P2860
P304
P356
10.1111/J.1471-4159.2008.05667.X
P407
P577
2008-09-11T00:00:00Z